Anti-VEGFR2 antibody therapy for hepatocellular carcinoma
AssigneeImClone LLC
InventorsPaolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang
Life of this patent
Estimating the term…
Abstract
The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.
Claims20
A method of selecting a patient having a hepatocellular tumor and treating said patient with a therapeutically effective amount of ramucirumab, comprising assaying for the level of alpha-fetoprotein in a plasma or serum sample taken from the patient, and selecting and treating the patient with a therapeutically effective amount of ramucirumab if the level of alpha-fetoprotein in the sample is 400 ng/mL or greater.
A therapeutic regimen for treating a patient with a hepatocellular tumor, comprising:
- (1) assaying for the level of alpha-fetoprotein in a plasma or serum sample taken from the patient, (2) selecting the patient for treatment with ramucirumab if the level of alpha-fetoprotein in the sample is 400 ng/mL or greater, and (3) administering ramucirumab to the patient if the level of alpha-fetoprotein in the sample is 400-ng/mL or greater.
A method of treating a hepatocellular tumor in a selected patient, comprising selecting the patient if a serum or plasma sample taken from the patient has an alpha-fetoprotein level of 400 ng/mL or greater, and administering a therapeutically effective amount of ramucirumab to the patient, selected as having a level of alpha-fetoprotein of 400 ng/mL or greater in the serum or plasma sample taken from the patient.
A method of treating a hepatocellular tumor in a selected patient, comprising selecting the patient if a serum or plasma sample taken from the patient has an alpha-fetoprotein level of 400 ng/mL or greater, and administering a therapeutically effective amount of an anti-VEGFR2 antibody to the patient selected as having a level of alpha-fetoprotein of 400 ng/mL or greater in the serum or plasma sample taken from the patient, wherein the anti-VEGFR2 antibody comprises two heavy chains, each with the amino acid sequence of SEQ ID NO:
- 1, and two light chains, each with the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.